Optimal clinical trial design using value of information methods with imperfect implementation.

Traditional sample size calculations for randomized clinical trials are based on the tests of hypotheses and depend on somewhat arbitrarily chosen factors, such as type I and II errors rates and the smallest clinically important difference. In response to this, many authors have proposed the use of methods based on the value of information as an alternative. Previous attempts have assumed perfect implementation, i.e. if current evidence favors the new intervention and no new information is sought or expected, all future patients will receive it. A framework is proposed to allow for this assumption to be relaxed. The profound effect that this can have on the optimal sample size and expected net gain is illustrated on two recent examples. In addition, a model for assessing the value of implementation strategies is proposed and illustrated.

[1]  Andrew R Willan,et al.  The Option Value of Delay in Health Technology Assessment , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  Matthew Kowgier,et al.  Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods , 2008, Clinical trials.

[3]  J Hornberger,et al.  The cost-benefit of a randomized trial to a health care organization. , 1998, Controlled clinical trials.

[4]  Darren McKay,et al.  External cephalic version beginning at 34 weeks' gestation versus 37 weeks' gestation: a randomized multicenter trial. , 2003, American journal of obstetrics and gynecology.

[5]  Hamid Pezeshk,et al.  A Bayesian cost–benefit approach to the determination of sample size in clinical trials , 2008, Statistics in medicine.

[6]  A. Briggs,et al.  Statistical Analysis of Cost-effectiveness Data: Willan/Statistical Analysis of Cost-effectiveness Data , 2006 .

[7]  B W Brown,et al.  The sample size for a clinical trial: A Bayesian–decision theoretic approach , 2001, Statistics in medicine.

[8]  Andrew R Willan,et al.  Expected value of information and decision making in HTA. , 2007, Health economics.

[9]  Andrew R Willan,et al.  Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp trial. , 2004, European journal of gastroenterology & hepatology.

[10]  E. Grace,et al.  Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment—Helicobacter pylori positive (CADET-Hp) randomised controlled trial , 2002, BMJ : British Medical Journal.

[11]  Andrew R Willan,et al.  Globally optimal trial design for local decision making. , 2009, Health economics.

[12]  G. Chapman,et al.  [Medical decision making]. , 1976, Lakartidningen.

[13]  Andrew R Willan,et al.  Time and expected value of sample information wait for no patient. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Andrew R Willan,et al.  Clinical decision making and the expected value of information , 2007, Clinical trials.

[15]  K Claxton,et al.  An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.

[16]  Andrew Briggs,et al.  Statistical Analysis of Cost-Effectiveness Data , 2006 .

[17]  Andrew R Willan,et al.  Optimal sample size determinations from an industry perspective based on the expected value of information , 2008, Clinical trials.

[18]  Andrew R Willan,et al.  The value of information and optimal clinical trial design , 2005, Statistics in medicine.

[19]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[20]  Karl Claxton,et al.  The Value of Implementation and the Value of Information: Combined and Uneven Development , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  J Halpern,et al.  Designing a cost-effective clinical trial. , 1995, Statistics in Medicine.

[22]  K M Thompson,et al.  A dynamic programming approach to the efficient design of clinical trials. , 2001, Journal of health economics.